BMS-986482 + nivolumab + rHuPH20

BMS-986482 + nivolumab + rHuPH20 is an investigational **combination therapy** under clinical study for the treatment of advanced solid tumors. - **BMS-986482** is a novel oral agent being investigated for its anti-tumor activity. - **Nivolumab** is a monoclonal antibody that inhibits the immune checkpoint protein PD-1 (Programmed cell death protein 1), thereby enhancing immune system response against cancer cells. - **rHuPH20** (recombinant human hyaluronidase PH20) is an enzyme that degrades hyaluronan in the subcutaneous (SC) space, improving the dispersion and absorption of co-administered therapeutics and enabling more rapid or increased SC drug delivery. rHuPH20 has no direct anti-cancer activity but acts as a permeation enhancer when combined with other agents[3][6]. This combination is delivered as part of Phase 1/2 clinical trials for patients with advanced solid tumors refractory to standard therapies[1][2][5][7]. The developers are evaluating safety, pharmacokinetics, and preliminary efficacy of the triplet regimen.